PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22892395-9	2012	Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan.	candesartan	148-159	peroxisome proliferator activated receptor gamma	Mus musculus	20-68	
26115674-9	2015	The neurorestorative effects of candesartan and telmisartan were reduced by concomitant administration of the peroxisome proliferator-activated receptor gamma (PPARgamma, encoded by PPARG) antagonist T0070907, showing the importance of PPARgamma activation for the neurorestorative effect of these sartans.	candesartan	32-43	peroxisome proliferator activated receptor gamma	Mus musculus	110-158	
26115674-9	2015	The neurorestorative effects of candesartan and telmisartan were reduced by concomitant administration of the peroxisome proliferator-activated receptor gamma (PPARgamma, encoded by PPARG) antagonist T0070907, showing the importance of PPARgamma activation for the neurorestorative effect of these sartans.	candesartan	32-43	peroxisome proliferator activated receptor gamma	Mus musculus	160-169	
26115674-9	2015	The neurorestorative effects of candesartan and telmisartan were reduced by concomitant administration of the peroxisome proliferator-activated receptor gamma (PPARgamma, encoded by PPARG) antagonist T0070907, showing the importance of PPARgamma activation for the neurorestorative effect of these sartans.	candesartan	32-43	peroxisome proliferator activated receptor gamma	Mus musculus	182-187	
26115674-9	2015	The neurorestorative effects of candesartan and telmisartan were reduced by concomitant administration of the peroxisome proliferator-activated receptor gamma (PPARgamma, encoded by PPARG) antagonist T0070907, showing the importance of PPARgamma activation for the neurorestorative effect of these sartans.	candesartan	32-43	peroxisome proliferator activated receptor gamma	Mus musculus	236-245	
22892395-0	2012	Candesartan, an angiotensin II AT1-receptor blocker and PPAR-gamma agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice.	candesartan	0-11	peroxisome proliferator activated receptor gamma	Mus musculus	56-66	
22892395-9	2012	Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan.	candesartan	148-159	peroxisome proliferator activated receptor gamma	Mus musculus	70-79	
22892395-9	2012	Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan.	candesartan	148-159	peroxisome proliferator activated receptor gamma	Mus musculus	187-196	
22892395-9	2012	Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan.	candesartan	274-285	peroxisome proliferator activated receptor gamma	Mus musculus	20-68	
22892395-9	2012	Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan.	candesartan	274-285	peroxisome proliferator activated receptor gamma	Mus musculus	70-79	
22892395-9	2012	Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan.	candesartan	274-285	peroxisome proliferator activated receptor gamma	Mus musculus	187-196	
17485025-9	2007	In adipose tissue, TAK-536 and candesartan reduced TNF-alpha expression but increased the expression of adiponectin, PPARgamma, C/EBalpha, and aP2.	candesartan	31-42	peroxisome proliferator activated receptor gamma	Mus musculus	117-126